While melanoma is less common than some other skin cancers, it is responsible for nearly
10,000 deaths in the USA each year alone. For many decades, very limited treatment …

BACKGROUND: Melanoma is an aggressive disease that accounts for approximately 75%
of skin cancer-related deaths. Historically, treatment options for patients with advanced …

Metastatic melanoma remains a lethal disease with a long-term remission rate of less than
10%. Despite many years of research, there has not been a new drug approved in this …

Opinion statement The overall survival for patients with metastatic melanoma ranges from
4.7 to 11 months, with a median survival of 8.5 months. Standard treatment for patients with …

In a relatively short period of time, treatment strategies for metastatic melanoma have
radically changed leading to an unprecedented improvement in patient survival. In this …

Cutaneous melanoma arises from the malignant transformation of skin melanocytes; its
incidence and mortality have been increasing steadily over the last 50 years, now …

Malignant melanoma contributes the majority of skin cancer related deaths and shows an
increasing incidence in the past years. Despite all efforts of early diagnosis, metastatic …

Melanoma is considered one of the immunogenic–if not the most immunogenic–
malignancies. This is based on several observations. 1. Spontaneous remissions occur …

In recent years, the introduction and Federal Drug Administration approval of immune
checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients …

Melanoma is one of the most common cancers in Western countries but has defied the trend
of reductions in age-adjusted mortality observed in most other cancers in recent years …